<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35066822</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1614-7499</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>25</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Environmental science and pollution research international</Title>
          <ISOAbbreviation>Environ Sci Pollut Res Int</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF-κB-p65/iNOS and SIRT1/PPARγ signaling pathways in rats.</ArticleTitle>
        <Pagination>
          <StartPage>37644</StartPage>
          <EndPage>37659</EndPage>
          <MedlinePgn>37644-37659</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11356-021-18252-1</ELocationID>
        <Abstract>
          <AbstractText>Ulcerative colitis (UC) is a common chronic, idiopathic inflammatory bowel disease associated with inflammatory perturbation and oxidative stress. Umbelliferone (UMB) is a potent anti-inflammatory and antioxidant coumarin derivative. Depending on the possible mechanisms, we aimed to explore and elucidate the therapeutic potential of UMB on UC-inflammatory response and oxidative injury-induced via intrarectal administration of acetic acid (AA) in rats. Animals were assigned into four groups: control group, UMB (30 mg/kg, oral)-treated group, AA-induced colitis model group (2 ml of AA; 3% v/v), and colitis treated with UMB group. The results showed that UMB improved macroscopic and histological tissue injury caused by the AA. Mechanistically, UMB reduced the elevated colonic TNF-α, IL-6, MPO, and VCAM-1 and downregulated the gene and protein expression of TLR4, NF-κB, and iNOS signaling factors, exhibiting potent anti-inflammatory effects. Moreover, UMB upregulated the gene and protein expression of both SIRT1 and PPARγ signaling pathways, thereby inhibiting both oxidative injury and inflammatory response. Conclusively, UMB protected rats against AA-induced UC by suppressing the TLR4/NF-κB-p65/iNOS signaling pathway and promoting the SIRT1/PPARγ signaling. Our results showed the effectiveness of UMB in alleviating the pathogenesis of UC and introduced it as a possible therapeutic applicant for clinical application.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Abdel-Wahab</LastName>
            <ForeName>Basel A</ForeName>
            <Initials>BA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, College of Pharmacy, Najran University, Najran, Kingdom of Saudi Arabia. basel_post@msn.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medical Pharmacology, College of Medicine, Assiut University, Assiut, Egypt. basel_post@msn.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alkahtani</LastName>
            <ForeName>Saad A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, College of Pharmacy, Najran University, Najran, Kingdom of Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alqahtani</LastName>
            <ForeName>Abdulsalam A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Kingdom of Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hassanein</LastName>
            <ForeName>Emad H M</ForeName>
            <Initials>EHM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Environ Sci Pollut Res Int</MedlineTA>
        <NlmUniqueID>9441769</NlmUniqueID>
        <ISSNLinking>0944-1344</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C495347">Tlr4 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014468">Umbelliferones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.13.39</RegistryNumber>
          <NameOfSubstance UI="C496318">Nos2 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.-</RegistryNumber>
          <NameOfSubstance UI="C488368">Sirt1 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.5.1.-</RegistryNumber>
          <NameOfSubstance UI="D056564">Sirtuin 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q40Q9N063P</RegistryNumber>
          <NameOfSubstance UI="D019342">Acetic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019342" MajorTopicYN="N">Acetic Acid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003093" MajorTopicYN="Y">Colitis, Ulcerative</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="Y">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052247" MajorTopicYN="Y">Nitric Oxide Synthase Type II</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047495" MajorTopicYN="Y">PPAR gamma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056564" MajorTopicYN="Y">Sirtuin 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051197" MajorTopicYN="Y">Toll-Like Receptor 4</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014468" MajorTopicYN="Y">Umbelliferones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acetic acid colitis</Keyword>
        <Keyword MajorTopicYN="N">MAPK/ERK</Keyword>
        <Keyword MajorTopicYN="N">PPARγ</Keyword>
        <Keyword MajorTopicYN="N">SIRT1</Keyword>
        <Keyword MajorTopicYN="N">TLR4/NF-κB-p65/iNOS</Keyword>
        <Keyword MajorTopicYN="N">Umbelliferone</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>20</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35066822</ArticleId>
        <ArticleId IdType="doi">10.1007/s11356-021-18252-1</ArticleId>
        <ArticleId IdType="pii">10.1007/s11356-021-18252-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abdel-Daim MM, Farouk SM, Madkour FF, Azab SS (2015) Anti-inflammatory and immunomodulatory effects of Spirulina platensis in comparison to Dunaliella salina in acetic acid-induced rat experimental colitis. Immunopharmacol Immunotoxicol 37:126–139. https://doi.org/10.3109/08923973.2014.998368</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08923973.2014.998368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Daim MM, El-Tawil OS, Bungau SG (2019) Atanasov AG Applications of antioxidants in metabolic disorders and degenerative diseases: Mechanistic approach. Oxid Med Cell Longev 2019:3</Citation>
        </Reference>
        <Reference>
          <Citation>Abdel-Wahab BA, Alkahtani SA, Elagab EAM (2020) Tadalafil alleviates cisplatin-induced reproductive toxicity through the activation of the Nrf2/HO-1 pathway and the inhibition of oxidative stress and apoptosis in male rats. Reprod Toxicol 96:165–174</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.reprotox.2020.06.015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Wahab BA, Alqhtani HM, Walbi IA et al (2021) Piclamilast mitigates 1, 2-dimethylhydrazine induced colon cancer in rats through modulation of Ras/PI3K/Akt/mTOR and NF-κβ signaling. Chem Biol Interact 350:109686</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cbi.2021.109686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alshabi AM, Abdel-Wahab BA, Khateeb MM (2021) Combined Treatment of alpha-Lipoic acid and Omega-3 Polyunsaturated Fatty Acids Mitigates Acetic Acid-Induced Colitis in Rats through Regulating Antioxidant Defenses, NF-kappa beta Signal Transduction, and Inflammatory Cytokine Profile. Lat Am J Pharm 40:1071–1083</Citation>
        </Reference>
        <Reference>
          <Citation>Annese V, Rogai F, Settesoldi A, Bagnoli S (2012) PPARγ in Inflammatory Bowel Disease. PPAR Res 2012:620839. https://doi.org/10.1155/2012/620839</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/620839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arafa E-SA, Mohamed WR, Zaher DM, Omar HA (2020) Gliclazide attenuates acetic acid-induced colitis via the modulation of PPARγ, NF-κB and MAPK signaling pathways. Toxicol Appl Pharmacol 391:114919</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2020.114919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asma B, Ranajoy C, Shankar M (2014) Oxidative stress: An essential factor in the pathogenesis of gastrointestinal mucosal disease. Physiol Rev 94:329–354</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00040.2012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bábíčková J, Tóthová Ľ, Lengyelová E et al (2015) Sex differences in experimentally induced colitis in mice: a role for estrogens. Inflammation 38:1996–2006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10753-015-0180-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bancroft JD, Gamble M (2008) Theory and practice of histological techniques. Elsevier health sciences, Amsterdam</Citation>
        </Reference>
        <Reference>
          <Citation>Bertin B, Dubuquoy L, Colombel J-F, Desreumaux P (2013) PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets 14:1501–1507</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/13894501113149990162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broom OJ, Widjaya B, Troelsen J et al (2009) Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol 158:272–280</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2249.2009.04033.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Camuesco D, Comalada M, Rodríguez-Cabezas ME et al (n.d.) Agustina, R., Indrawati, T., D., Masruhin, M., A., 2015, Aktivitas Ekstrak Daun Salam (Eugenia Polyantha) sebagai Antiinflamasi pada Tikus Putih (Rattus Norvergicus), J. Trop. Pharm. Chem. Vol 3. No 2. Anief, M., 2000, Ilmu Meracik Obat, Cetakan ke sembilan, 169, Gadjah Mada UI Press, Yogyakarta. Pharmacology 143:908–918</Citation>
        </Reference>
        <Reference>
          <Citation>Cargnello M, Roux PP (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75:50–83. https://doi.org/10.1128/MMBR.00031-10</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MMBR.00031-10</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cario E (2010) Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 16:1583–1597. https://doi.org/10.1002/ibd.21282</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ibd.21282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caruso R, Marafini I, Franzè E et al (2014) Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut. Mucosal Immunol 7:1467–1479</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mi.2014.35</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen F, Wang M, O’Connor JP et al (2003) Phosphorylation of PPARγ via active ERK1/2 leads to its physical association with p65 and inhibition of NF-κβ. J Cell Biochem 90:732–744</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.10668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Souza HSP, Fiocchi C (2016) Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 13:13</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrgastro.2015.186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubuquoy L, Rousseaux C, Thuru X et al (2006) PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 55:1341–1349</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2006.093484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elshazly SM, Elhassanny AEM, Mahmoud NM (2020) Cilostazol protects against acetic acid-induced colitis in rats: possible role for cAMP/SIRT1 pathway. Eur J Pharmacol 881:173234</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2020.173234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engler A, Tange C, Frank-Bertoncelj M et al (2016) Regulation and function of SIRT1 in rheumatoid arthritis synovial fibroblasts. J Mol Med 94:173–182</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00109-015-1332-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan H, Yang H-C, You L et al (2013) The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury. Kidney Int 83:404–413</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ki.2012.394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedrich M, Pohin M, Powrie F (2019) Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. Immunity 50:992–1006. https://doi.org/10.1016/j.immuni.2019.03.017</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2019.03.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukata M, Abreu MT (2008) Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 27:234–243. https://doi.org/10.1038/sj.onc.1210908</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1210908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghafari H, Yasa N, Mohammadirad A et al (2006) Protection by Ziziphora clinopoides of acetic acid-induced toxic bowel inflammation through reduction of cellular lipid peroxidation and myeloperoxidase activity. Hum Exp Toxicol 25:325–332</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1191/0960327105ht626oa</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haigis MC, Sinclair DA (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol Mech Dis 5:253–295</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.pathol.4.110807.092250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harbord M, Eliakim R, Bettenworth D et al (2017) European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 11:769–784</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ecco-jcc/jjx009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassanein EHM, Mohamed WR, Shalkami A-GS et al (2018) Renoprotective effects of umbelliferone on methotrexate-induced renal injury through regulation of Nrf-2/Keap-1, P38MAPK/NF-κB, and apoptosis signaling pathways. Food Chem Toxicol 116:152–160</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fct.2018.03.041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassanein EHM, Ali FEM, Kozman MR, Abd El-Ghafar OAM (2021) Umbelliferone attenuates gentamicin-induced renal toxicity by suppression of TLR-4/NF-κB-p65/NLRP-3 and JAK1/STAT-3 signaling pathways. Environ Sci Pollut Res 28:11558–11571</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11356-020-11416-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hazel K, O’Connor A (2020) Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis 11:2040622319899297</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2040622319899297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Z, Zhou Q, Wen K et al (2019) Huangkui lianchang decoction ameliorates dss-induced ulcerative colitis in mice by inhibiting the nf-kappab signaling pathway. Evid Based Compl Altern Med 2019:1–11</Citation>
        </Reference>
        <Reference>
          <Citation>Hirten RP, Sands BE (2021) New Therapeutics for Ulcerative Colitis. Annu Rev Med 72:199–213</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-med-052919-120048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iside C, Scafuro M, Nebbioso A, Altucci L (2020) SIRT1 Activation by Natural Phytochemicals: An Overview. Front Pharmacol 11:1225. https://doi.org/10.3389/fphar.2020.01225</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.01225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung YJ, Lee JE, Lee AS et al (2012) SIRT1 overexpression decreases cisplatin-induced acetylation of NF-κB p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem Biophys Res Commun 419:206–210</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2012.01.148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>K Ko J, K Auyeung K (2014) Inflammatory bowel disease: etiology, pathogenesis and current therapy. Curr Pharm Des 20:1082–1096</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/13816128113199990416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kauppinen A, Suuronen T, Ojala J et al (2013) Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal 25:1939–1948</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2013.06.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH, Jung YJ, Lee JE et al (2011) SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Physiol 301:F427–F435</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajprenal.00258.2010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YJ, Kim E, Hahm KB (2012) Oxidative stress in inflammation-based gastrointestinal tract diseases: Challenges and opportunities. J Gastroenterol Hepatol 27:1004–1010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1746.2012.07108.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S, Kang M, Kang C et al (2019) Anti-inflammatory effects of 6-formyl umbelliferone via the NF-κB and ERK/MAPK pathway on LPS-stimulated RAW 264.7 cells. Int J Mol Med 43:1859–1865</Citation>
        </Reference>
        <Reference>
          <Citation>Kimura H, Hokari R, Miura S et al (1998) Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 42:180–187</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.42.2.180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krawisz JE, Sharon P, Stenson WF (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: assessment of inflammation in rat and hamster models. Gastroenterology 87:1344–1350</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0016-5085(84)90202-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruger NJ (2009) The Bradford method for protein quantitation. The protein protocols handbook. pp 17–24</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-59745-198-7_4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lakatos P-L, Lakatos L (2008) Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 14:3937–3947. https://doi.org/10.3748/wjg.14.3937</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.14.3937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Zhang L, Joo D, Sun S-C (2017) NF-κB signaling in inflammation. Signal Transduct Target Ther 2:17023. https://doi.org/10.1038/sigtrans.2017.23</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sigtrans.2017.23</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 25:402–408</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Low D, Nguyen DD, Mizoguchi E (2013) Animal models of ulcerative colitis and their application in drug research. Drug Des Devel Ther 7:1341</Citation>
        </Reference>
        <Reference>
          <Citation>Luo H, Fan Z, Xiang D et al (2018) The protective effect of umbelliferone ameliorates myocardial injury following ischemia-reperfusion in the rat through suppression NLRP3 inflammasome and upregulating the PPAR-γ. Mol Med Rep 17:3404–3410</Citation>
        </Reference>
        <Reference>
          <Citation>Mahmoud AS, Abd El Motteleb DM, Mahmoud NM, Mahmoud SS (2021) Protective Effect of Agomelatine against Acetic Acid-Induced Ulcerative Colitis in Male Albino Rats. Ann Rom Soc Cell Biol 25:13323–13343</Citation>
        </Reference>
        <Reference>
          <Citation>Mazimba O (2017) Umbelliferone: Sources, chemistry and bioactivities review. Bull Fac Pharmacy, Cairo Univ 55:223–232. https://doi.org/10.1016/j.bfopcu.2017.05.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bfopcu.2017.05.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirza AZ, Althagafi II, Shamshad H (2019) Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Eur J Med Chem 166:502–513</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2019.01.067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mollà M, Gironella M, Miquel R et al (2003) Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. Int J Radiat Oncol Biol Phys 57:264–273</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0360-3016(03)00523-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muthu R, Selvaraj N, Vaiyapuri M (2016) Anti-inflammatory and proapoptotic effects of umbelliferone in colon carcinogenesis. Hum Exp Toxicol 35:1041–1054</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0960327115618245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurath MF (2014) Cytokines in inflammatory bowel disease. Nat Rev Immunol 14:329–342</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurath MF, Finotto S (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22:83–89</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cytogfr.2011.02.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niu X, Zhang H, Li W et al (2015) Protective effect of cavidine on acetic acid-induced murine colitis via regulating antioxidant, cytokine profile and NF-κB signal transduction pathways. Chem Biol Interact 239:34–45</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cbi.2015.06.026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novak EA, Mollen KP (2015) Mitochondrial dysfunction in inflammatory bowel disease. Front Cell Dev Biol 3:62</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2015.00062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olmos Y, Sánchez-Gómez FJ, Wild B et al (2013) SirT1 regulation of antioxidant genes is dependent on the formation of a FoxO3a/PGC-1α complex. Antioxid Redox Signal 19:1507–1521. https://doi.org/10.1089/ars.2012.4713</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2012.4713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osaki LH, Gama P (2013) MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. Int J Mol Sci 14:10143–10161. https://doi.org/10.3390/ijms140510143</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms140510143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedersen G, Brynskov J (2010) Topical Rosiglitazone Treatment Improves Ulcerative Colitis by Restoring Peroxisome Proliferator-Activated Receptor- Activity. Am J Gastroenterol 105:1595–1603. https://doi.org/10.1038/ajg.2009.749</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ajg.2009.749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pham J, Rajan KAN, Li P, Parast MM (2018) The role of Sirtuin1–PPARγ axis in placental development and function. J Mol Endocrinol 60:R201–R212</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/JME-17-0315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramesh B, Pugalendi KV (2006) Antihyperglycemic effect of umbelliferone in streptozotocin-diabetic rats. J Med Food 9:562–566</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/jmf.2006.9.562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos-Vara JA, Miller MA (2014) When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry—the red, brown, and blue technique. Vet Pathol 51:42–87</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0300985813505879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Randhawa PK, Singh K, Singh N, Jaggi AS (2014) A review on chemical-induced inflammatory bowel disease models in rodents. Korean J Physiol Pharmacol 18:279–288</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4196/kjpp.2014.18.4.279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salim T, Sershen CL, May EE (2016) Investigating the Role of TNF-α and IFN-γ Activation on the Dynamics of iNOS Gene Expression in LPS Stimulated Macrophages. PLoS ONE 11:e0153289–e0153289. https://doi.org/10.1371/journal.pone.0153289</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0153289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saniabadi AR, Tanaka T, Ohmori T et al (2014) Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J Gastroenterol 20:9699–9715. https://doi.org/10.3748/wjg.v20.i29.9699</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i29.9699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sayed AM, Hassanein EHM, Salem SH et al (2020) Flavonoids-mediated SIRT1 signaling activation in hepatic disorders. Life Sci 259:118173</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2020.118173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schottelius AJG, Baldwin AS Jr (1999) A role for transcription factor NF-kB in intestinal inflammation. Int J Colorectal Dis 14:18–28</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s003840050178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano-Marco L, Chacón MR, Maymó-Masip E et al (2012) TNF-α inhibits PPARβ/δ activity and SIRT1 expression through NF-κB in human adipocytes. Biochim Biophys Acta Molec Cell Biol Lipids 1821:1177–1185</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbalip.2012.05.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siebert A, Goren I, Pfeilschifter J, Frank S (2016) Anti-inflammatory effects of rosiglitazone in obesity-impaired wound healing depend on adipocyte differentiation. PLoS One 11:e0168562</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0168562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soriano A, Salas A, Salas A et al (2000) VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Investig 80:1541–1551</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.3780164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stevens C, Walz G, Singaram C et al (1992) Tumor necrosis factor-α, interleukin-1β, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 37:818–826</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01300378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci 76:4350–4354</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.76.9.4350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Triantafillidis JK, Merikas E, Georgopoulos F (2011) Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 5:185</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/DDDT.S11290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsikas D (2007) Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. J Chromatogr B 851:51–70</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jchromb.2006.07.054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Weemen B, Schuurs A (1971) Immunoassay using antigen—enzyme conjugates. FEBS Lett 15:232–236</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-5793(71)80319-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villapol S (2018) Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation. Cell Mol Neurobiol 38:121–132</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10571-017-0554-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D, Wang X, Tong W et al (2019a) Umbelliferone alleviates lipopolysaccharide-induced inflammatory responses in acute lung injury by down-regulating TLR4/MyD88/NF-κB signaling. Inflammation 42:440–448</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10753-018-00953-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang G, Xu B, Shi F et al (2019b) Protective Effect of Methane-Rich Saline on Acetic Acid-Induced Ulcerative Colitis via Blocking the TLR4/NF-κB/MAPK Pathway and Promoting IL-10/JAK1/STAT3-Mediated Anti-inflammatory Response. Oxid Med Cell Longev 2019:7850324. https://doi.org/10.1155/2019/7850324</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/7850324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Chen G, Lu L, Zou H (2019c) Sirt1 inhibits gouty arthritis via activating PPARγ. Clin Rheumatol 38:3235–3242</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-019-04697-w</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie J, Zhang X, Zhang L (2013) Negative regulation of inflammation by SIRT1. Pharmacol Res 67:60–67</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2012.10.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Zhang W, Pan H et al (2012) SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. PLoS One 7:e46364</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0046364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao D, Dong M, Dai C, Wu S (2019) Inflammation and inflammatory cytokine contribute to the initiation and development of ulcerative colitis and its associated cancer. Inflamm Bowel Dis 25:1595–1602</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ibd/izz149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeung AWK, Tzvetkov NT, El-Tawil OS et al (2019) Antioxidants: Scientific Literature Landscape Analysis. Oxid Med Cell Longev 2019:8278454. https://doi.org/10.1155/2019/8278454</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/8278454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin J, Wang H, Lu G (2018) Umbelliferone alleviates hepatic injury in diabetic db/db mice via inhibiting inflammatory response and activating Nrf2-mediated antioxidant. Biosci Rep 38(4):BSR20180444</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BSR20180444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youn J, Lee J-S, Na H-K et al (2009) Resveratrol and piceatannol inhibit iNOS expression and NF-κ B activation in dextran sulfate sodium-induced mouse colitis. Nutr Cancer 61:847–854</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/01635580903285072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaidi D, Wine E (2018) Regulation of Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κβ) in Inflammatory Bowel Diseases. Front Pediatr 6:317</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fped.2018.00317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang G, Ghosh S (2001) Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 107:13–19. https://doi.org/10.1172/JCI11837</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI11837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, Huang Q, Zeng Z et al (2017) Sirt1 Inhibits Oxidative Stress in Vascular Endothelial Cells. Oxid Med Cell Longev 2017:7543973. https://doi.org/10.1155/2017/7543973</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/7543973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Xue H, Zhao G et al (2019) Curcumin and resveratrol suppress dextran sulfate sodium-induced colitis in mice. Mol Med Rep 19:3053–3060</Citation>
        </Reference>
        <Reference>
          <Citation>Zhu X, Liu Q, Wang M et al (2011) Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts. PLoS One 6:e27081</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0027081</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
